{
  "docId": "019dd923-622c-750b-8b9a-3bcd52c6e583",
  "docSlug": "f06b0b5d2079",
  "documentTitle": "Soleno Therapeutics (SLNO)",
  "authorId": "58_Scorpion_Capital",
  "authorName": "Scorpion Capital",
  "documentKindSlug": "activist-deck",
  "documentKindLabel": "Activist deck",
  "sourceTypeSlug": "short_seller",
  "sourceTypeLabel": "Short seller",
  "presentationDate": "2025-08-15 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.3333334,
  "pageNumber": 385,
  "pageCount": 415,
  "prevPage": 384,
  "nextPage": 386,
  "slideType": "quote_slide",
  "function": "expose_contradiction",
  "density": "dense",
  "nDataPoints": 0,
  "notes": "The slide highlights a potential safety concern raised by an expert, specifically regarding pre-diabetic and obese patients.",
  "elementsJson": [
    "paragraph",
    "quote_block",
    "footnote"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-622c-750b-8b9a-3bcd52c6e583/385",
  "deckHref": "/decks/019dd923-622c-750b-8b9a-3bcd52c6e583",
  "deckJsonHref": "/decks/019dd923-622c-750b-8b9a-3bcd52c6e583.json",
  "deckAnchorHref": "/decks/019dd923-622c-750b-8b9a-3bcd52c6e583#slide-385",
  "components": [
    {
      "bbox": null,
      "kind": "callout",
      "text": "I would be most concerned about starting this medicine in someone that was pre-diabetic...the people that I'm the most concerned about are those borderline A1c patients that are obese and pre-diabetic...and I hesitate to start this medicine, and if I am, then I'm having a conversation about stopping it if they develop diabetes.",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd953-64ce-7561-b2b6-5ae4004e9127",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.025,
        "w": 0.765,
        "x": 0.073,
        "y": 0.318
      },
      "kind": "paragraph",
      "text": "Concerned about diabetes risk especially in pre-diabetic patients; inherent to Vykat mechanism of action",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3fb798b4-3fb0-4cae-8a90-49c51edb3810",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.135,
        "w": 0.905,
        "x": 0.073,
        "y": 0.345
      },
      "kind": "quote",
      "text": "Q: “How do you think about the risk of diabetes with this mechanism of action?”\nA: “Yes, I would say that the mechanism of action for why they have less hyperphagia is that it's on the same channel that also participates in the insulin production. I would be most concerned about starting this medicine in someone that was pre-diabetic...the people that I'm the most concerned about re those borderline A1c patients that are obese and pre-diabetic. And I hesitate to start this medicine, and if I am, then I'm having a conversation about stopping it if they develop diabetes.” - Pediatric endocrinologist, leads one of the largest PWS clinics in US with 30-40 patients; 11 endocrinologists, major academic center",
      "attrs": null,
      "subkind": "testimonial",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "31eb8c55-f9f9-4a6e-a199-377264388d69",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "quote",
      "text": "“Yes, I would say that the mechanism of action for why they have less hyperphagia is that it's on the same channel that also participates in the insulin production. I would be most concerned about starting this medicine in someone that was pre-diabetic...the people that I'm the most concerned about re those borderline A1c patients that are obese and pre-diabetic. And I hesitate to start this medicine, and if I am, then I'm having a conversation about stopping it if they develop diabetes.” — Pediatric endocrinologist, leads one of the largest PWS clinics in US with 30-40 patients; 11 endocrinologists, major academic center",
      "attrs": null,
      "subkind": null,
      "toolName": "Authority citation",
      "toolSlug": "authority-citation",
      "confidence": null,
      "componentId": "019dd953-64ce-7561-b2b6-5dec6e53cae3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.31,
        "x": 0.073,
        "y": 0.95
      },
      "kind": "source-note",
      "text": "Source: Scorpion Capital consultation calls with experts",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d49bf97b-6ad3-4f99-b69a-4a7eaf50ae5d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.18,
        "w": 0.854,
        "x": 0.073,
        "y": 0.07
      },
      "kind": "title",
      "text": "The endocrinologist indicated concern that Vykat’s mechanism of action may cause diabetes – “I would be most concerned about starting this medicine in someone that was pre-diabetic...the people that I'm the most concerned about are those borderline A1c patients that are obese and pre-diabetic...and I hesitate to start this medicine, and if I am, then I'm having a conversation about stopping it if they develop diabetes.”",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3d9251b3-0e01-4d30-b7cc-918d1ad6bc24",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}